DOI: 10.1128/AAC.02419-17
Article Information
PubMed
Published By
History
- Received November 24, 2017
- Returned for modification December 30, 2017
- Accepted February 24, 2018
- Published online April 26, 2018.
Copyright & Usage
Copyright © 2018 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (March 05, 2018).
- You are viewing the most recent version of this article.
Author Information
- Katrien Van Bocxlaera,
- Eric Gaukelb,
- Deirdre Hauserb,
- Seong Hee Parkb,
- Sara Schockb,
- Vanessa Yardleya,
- Ryan Randolphb,
- Jacob J. Plattnerc,
- Tejal Merchantc,
- Simon L. Crofta,
- Robert T. Jacobsc and
- Stephen A. Wringb
- aLondon School of Hygiene & Tropical Medicine, Faculty of Infections and Tropical Diseases, London, United Kingdom
- bScynexis Inc., Research Triangle Park, North Carolina, USA
- cAnacor Pharmaceuticals, Inc., Palo Alto, California, USA
- Address correspondence to Simon L. Croft, simon.croft{at}lshtm.ac.uk.
Citation Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA. 2018. Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles. Antimicrob Agents Chemother 62:e02419-17. https://doi.org/10.1128/AAC.02419-17.
